OncoMatch/Clinical Trials/NCT06716658
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Is NCT06716658 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies JAK1 Inhibitor for lymphoma, t-cell.
Treatment: JAK1 Inhibitor — Indolent T/NK-cell lymphomas are a heterogeneous group of lymphoproliferative diseases originating from T/NK cells, characterized by slow growth and proliferation, but currently remain incurable. For indolent T/NK-cell lymphomas that are unresponsive to first-line treatment, there are few treatment options available and the prognosis is poor. This study is an open-label, prospective clinical trial aimed at evaluating the feasibility, efficacy, and safety of PI3K inhibitors in the treatment of relapsed/refractory indolent T/NK-cell lymphomas. Patients will be treated with Golidocitnib, with an expected overall response rate of 60% for JAK1 inhibitor Golidocitnib treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy
lymphoma that has failed at least one systemic therapy or is intolerant to such treatment and/or currently has no effective standard treatment options
Cannot have received: JAK inhibitor
Subjects who have previously used any JAK inhibitors
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: within 90 days prior to the first dose of study treatment
Subjects who have undergone autologous hematopoietic stem cell transplantation within 90 days prior to the first dose of study treatment
Lab requirements
Kidney function
blood urea nitrogen (bun)/urea and creatinine (cr) ≤ 1.5 × uln
Liver function
total bilirubin (tbil) ≤ 1.5 × uln; alt and ast ≤ 2.5 × uln
Cardiac function
left ventricular ejection fraction (lvef) ≥ 50%; fridericia-corrected qt interval (qtcf): < 450 ms for males, < 470 ms for females
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify